Psychological Treatment in Psychiatric Inpatient Care

December 13, 2023 updated by: Marten Tyrberg, Uppsala University
This study aims to investigate the effect of a brief psychotherapeutic treatment intervention based on ACT, aimed specifically at the vulnerable group of patients in psychiatric 24-hour care treated according to LPT. The study aims to investigate whether a brief number of therapeutic sessions according to ACT during inpatient care produce positive effects on personally relevant life areas for a diagnostically mixed group of patients in a psychiatric intensive care unit.

Study Overview

Study Type

Interventional

Enrollment (Actual)

1

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Västmanland
      • Västerås, Västmanland, Sweden, 72189
        • Hospital of Västmanland, Västerås

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18 years old or older.
  • Treated according to the compulsory psychiatric care act.
  • Meet the criterion of informed consent.

Exclusion Criteria:

  • Lack the cognitive ability to acquire the treatment intervention, such as impaired attention, memory, logic and reasoning, and also auditory and visual processing. This will be based on a clinical assessment by the ward team, including the attending psychiatrist and a clinical psychologist.
  • Ongoing psychological treatment parallel to the admission.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acceptance & Commitment Therapy (ACT)
Psyhotherapy based on principles of functional analysis, behavioral activation, and experiential avoidance.

The treatment is based on a variant of CBT, as briefly referred to before, ACT. In short, the treatment consists of identifying central and important areas of life, and how to approach these even though you are also struggling with persistent and challenging problems. In this study, the treatment intervention is flexibly constructed, focusing on several central principles based on ACT. These can be applied during one or numerous sessions.

The intervention is a flexible application of clinical functional analysis, as well as a couple of selected interventions which, in terms of experience and in previous studies, have been shown to work well for the current group (24-hour psychiatric patients with complex problems) and which are individually adaptable to the nature of the problem and degree.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Personal Questionnaire
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
Scores range from 1-4 per item (number of items might differ between patients as the measure is individually constructed. Higher scores correspond to worse outcome.
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
Change in Bull's Eye Values Survey
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
The score ranges from 0-28, higher scores corresponding to better outcome.
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
Change in PHQ-9
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
The score ranges from 0-27, higher scores corresponding to worse outcome.
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
Change in GAD-7
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
The score ranges from 0-21, higher scores corresponding to worse outcome.
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
Change in Psy-flex
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
The score ranges from 6-30, higher scores corresponding to better outcome.
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Kent Nilsson, Professor, Uppsala University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2023

Primary Completion (Actual)

November 15, 2023

Study Completion (Actual)

November 15, 2023

Study Registration Dates

First Submitted

April 28, 2023

First Submitted That Met QC Criteria

August 21, 2023

First Posted (Actual)

August 28, 2023

Study Record Updates

Last Update Posted (Actual)

December 20, 2023

Last Update Submitted That Met QC Criteria

December 13, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 280468

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychosis

Clinical Trials on ACT

3
Subscribe